BASEL, Switzerland, June 21, 2004 (PRIMEZONE) -- Basilea Pharmaceutica announced today that it has appointed Rienk Pypstra MD as Chief Development Officer.
Dr. Pypstra, who has served as Basilea's Head of Infectious Diseases since October 2003, was formerly Global Pharmacology Head of Infectious Diseases and Host Defence at GlaxoSmithKline in Philadelphia.
"We are delighted to make this key appointment. We now have commercialisation rights on two significant late stage products and we successfully delivered on earlier milestones. This clearly signals our intent to maintain our strong international drug development capabilities to drive these products towards marketing approval," said Anthony Man MD, Basilea CEO.
About Basilea
Basilea Pharmaceutica AG (BSLN) is an independent biopharmaceutical company headquartered in Basel, Switzerland that is actively engaged in the discovery and development of innovative medicines for the treatment of unmet medical needs.
The company's fully integrated research and development operations are currently focused on new anti-bacterial, anti-fungal and dermatology drugs. Basilea was founded in October 2000 with significant resources to discover, develop and bring innovative medicines to market. Basilea is listed on the SWX Swiss Exchange.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact the following: